Skip to content

Conventional Dose Versus High Dose Sequential Chemotherapy for Poor Prognosis Germ Cell Tumors

Randomized Phase 2 Study of Conventional Dose Chemotherapy Versus High Dose Sequential Chemotherapy as First-line Therapy for Metastatic Poor Prognosis Germ Cell Tumors

Status
Completed
Phases
Phase 2
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT02161692
Enrollment
Unknown
Registered
2014-06-12
Start date
1996-12-31
Completion date
2009-04-30
Last updated
2014-06-12

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Germ Cell Tumors, Testicular Neoplasms

Brief summary

The purpose of this study is to determine whether the use of a sequential high dose chemotherapy is more effective than conventional dose (i.e. 4 cycles of cisplatin, etoposide, and bleomycin \[PEB\]) in patients with metastatic poor prognosis germ cell tumors.

Interventions

DRUGCyclophosphamide
DRUGEtoposide
DRUGCisplatin
DRUGBleomycin
DRUGCarboplatin

High dose carboplatin

Sponsors

Fondazione IRCCS Istituto Nazionale dei Tumori, Milano
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
MALE
Age
18 Years to 75 Years
Healthy volunteers
No

Inclusion criteria

* Clinical or Histological diagnosis of germ cell tumors * Metastatic disease * Poor prognostic category according to the International Germ Cell Collaborative Group (IGCCCG) classification * No prior chemotherapy for metastatic disease

Exclusion criteria

* Unwillingness to accomplish the study procedures * Any existing co-morbidity that could limit the administration of high dose chemotherapy * Any psychiatric disorder that could impact on the study compliance

Design outcomes

Primary

MeasureTime frame
Evidence of disease progression confirmed by computed tomography (CT) scan and/or serum tumor markers.5 years

Secondary

MeasureTime frame
Overall survival5 years

Countries

Italy

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Mar 19, 2026